Illustrative image (Photo: Nanogen) Hanoi (VNA) – The National Ethics Committee in
Biomedical Research under the has requested additional
reports on the protective efficacy of the homegrown candidate COVID-19 vaccine Nano Covax, requiring that they should be submitted before 3pm on December 22 for review.
The ministry announced on December 20 that on
December 16, the committee convened a meeting reviewing supplementary reports on the mid-term outcomes of the phase 3
trial of Nano Covax as of November 30.
Accordingly, it concluded that Nano Covax met safety
requirements based on data of the additional reports. It also met requirements on immunity
production in accordance with the ministry’s professional guidelines.
However, more data on its efficacy are needed, the said.
Nano Covax, a recombinant spike protein
vaccine, is the forerunner in the race for domestically produced
vaccine, followed by COVIVAC from the Institute of Vaccines and Biologic
Medical and mRNA vaccine ARCT-154 (by Arcturus and VinBioCare) just
starting phase 2 trials.
Developed by the Nanogen Pharmaceutical
Biotechnology JSC based on recombinant DNA/protein technology, Nano Covax went
through the first-phase trial from December 18, 2020 and the second phase from
February 26, 2021. The third phase started on June 11, 2021.
Results from the first two trial phases showed
that all volunteers developed antibodies against the coronavirus SARS-CoV-2./.
Source: VietnamPlus
